Exploration of Biomarkers for Systemic Treatment of Renal Cell Carcinoma Through Longitudinal Monitoring of Peripheral Blood Immune Cells

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K16747
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: Fukuda Hironori 東京女子医科大学, 医学部, 助教 (60848951)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 腎細胞がん / 免疫チェックポイント阻害剤 / 末梢血免疫細胞 / バイオマーカー

Outline of Final Research Achievements

In this study, we analyzed whether peripheral blood immune cells correlate with the therapeutic effect of immune checkpoint inhibitors in metastatic renal cell carcinoma. Flow cytometry and comprehensive single-cell gene expression analysis were performed for the analysis. As a result, we identified several clusters that correlate with therapeutic effects and obtained results that could lead to the establishment of biomarkers for predicting therapeutic effects. In the future, it will be necessary to validate these results using a larger number of samples.

Free Research Field

泌尿器科

Academic Significance and Societal Importance of the Research Achievements

この研究の社会的意義は、末梢血のデータから免疫チェックポイント阻害剤の治療効果を予測するバイオマーカーを見出すことで、今後の個別化されたがん治療に向けた情報として重要な点にある。採取する侵襲度が少ない末梢血から治療効果が予測できれば、治療効果が期待できる患者を安全に選択することができ、患者の生活の質を向上させる治療戦略を開発する基盤を提供することが期待される。